| Trial ID: | L6550 |
| Source ID: | NCT01253278
|
| Associated Drug: |
Ly2393910
|
| Title: |
A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY2393910|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of Participants with Clinically Significant Effects, Over four weeks | Secondary: Pharmacokinetics of LY2393910, Area Under the Curve (AUC), From predose Day 1 up until Day 19|Change from baseline to day 28 in glucagon, Baseline, day 28|Pharmacokinetics of LY2393910, maximum concentration (Cmax), From predose Day 1 up until Day 19|Change from baseline to day 28 in glucose-like peptide 1 (GLP-1), Baseline, day 28|Change from baseline to day 14 in insulin, baseline, day 14|Change from baseline to day 14 in proinsulin, baseline, day 14|Change from baseline to day 28 in glucose, baseline, day 28|Change from baseline to day 14 in C-peptide, baseline, day 14
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose:
|
| Start Date: |
2010-03
|
| Completion Date: |
2011-05
|
| Results First Posted: |
|
| Last Update Posted: |
2011-06-10
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, D-41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01253278
|
